Skip to main content
. 2018 Oct 15;36(1):47–54. doi: 10.5114/biolsport.2018.78906

TABLE 2.

Study results from baseline (W0) to follow-ups (W2 to W6).

  week SIT (n = 10)
ET (n = 10)
CG (n = 10)
mean ± SD p-value d mean ± SD p-value d mean ± SD p-value d
⩒Lamax [mmol∙L-1∙s-1] W0 0.76 ± 0.18     0.75 ± 0.18     0.75 ± 0.18    
W2 0.67 ± 0.17 0.01 -0.48 0.76 ± 0.18 0.99 0.01 0.75 ± 0.18 0.99 0.02
W4 0.63 ± 0.17 0.01 -0.71 0.74 ± 0.17 0.99 -0.06 0.73 ± 0.18 0.99 -0.10
W6 0.63 ± 0.15 0.01 -0.78 0.74 ± 0.17 0.99 -0.08 0.75 ± 0.21 0.99 0.03

LaPre [mmol∙L-1∙s-1] W0 1.04 ± 0.46     1.19 ± 0.6     1.12 ± 0.34    
W2 0.94 ± 0.55 0.99 -0.21 1.11 ± 0.56 0.99 -0.13 0.97 ± 0.21 0.54 -0.54
W4 0.86 ± 0.37 0.04 -0.44 1.02 ± 0.62 0.52 -0.28 0.94 ± 0.31 0.64 -0.53
W6 0.85 ± 0.21 0.04 -0.56 0.92 ± 0.56 0.05 -0.48 1.11 ± 0.42 0.99 -0.03

LamaxPost [mmol∙L-1∙s-1] W0 9.05 ± 2.42     9.21 ± 2.14     9.43 ± 2.24    
W2 7.82 ± 1.91 0.02 -0.56 9.30 ± 1.92 0.99 0.04 9.44 ± 2.30 0.99 0.01
W4 7.57 ± 2.16 0.01 -0.65 8.92 ± 2.2 0.99 -0.14 9.03 ± 2.37 0.99 -0.17
W6 7.48 ± 1.55 0.01 -0.79 8.75 ± 1.99 0.99 -0.22 8.99 ± 2.08 0.99 -0.20

Ladiff [mmol∙L-1] W0 8.01 ± 2.09     8.02 ± 1.91     8.31 ± 2.09    
W2 6.89 ± 1.57 0.02 -0.61 8.18 ± 1.85 0.99 0.09 8.48 ± 2.18 0.99 0.08
W4 6.71 ± 1.85 0.01 -0.66 7.90 ± 1.86 0.99 -0.06 8.08 ± 2.33 0.99 -0.10
W6 6.63 ± 1.44 0.01 -0.78 7.83 ± 1.76 0.99 -0.10 7.88 ± 1.79 0.99 -0.22

talac [s] W0 3.84 ± 0.37     4.45 ± 0.61     4.14 ± 0.72    
W2 3.83 ± 0.53 0.99 -0.02 4.36 ± 0.49 0.99 -0.15 4.01 ± 0.60 0.79 -0.20
W4 4.07 ± 0.50 0.29 0.52 4.41 ± 0.47 0.99 -0.07 4.09 ± 0.65 0.99 -0.08
W6 3.77 ± 0.38 0.99 -0.21 4.34 ± 0.57 0.99 -0.18 4.05 ± 0.69 0.99 -0.13

Pmax [W] W0 1066 ± 138     943 ± 180     1039 ± 170    
W2 1036 ± 157 0.14 -0.21 951 ± 190 0.99 0.05 1017 ± 172 0.51 -0.13
W4 1035 ± 178 0.99 -0.19 948 ± 200 0.99 0.03 1004 ± 168 0.75 -0.21
W6 1018 ± 164 0.33 -0.32 958 ± 202 0.99 0.08 1025 ± 176 0.99 -0.08

SDp15 [W] W0 160.5 ± 40.2     139.5 ± 25.0     154.2 ± 43.0    
W2 141.6 ± 36.2 0.04 -0.50 134.5 ± 26.7 0.99 -0.19 148.4 ± 41.4 0.99 -0.14
W4 127.8 ± 44.0 0.01 -0.78 134.7 ± 30.0 0.99 -0.18 146.5 ± 45.0 0.35 -0.18
W6 128.6 ± 35.4 0.01 -0.85 135.6 ± 29.9 0.99 -0.14 146.1 ± 44.5 0.99 -0.18

⩒O2max [ml∙kg-1∙min-1] W0 62.6 ± 8.8     61.0 ± 4.8     60.8 ± 9.0    
W2 62.8 ± 6.6 0.99 0.03 63.9 ± 4.2 0.03 0.63 60.8 ± 7.5 0.99 0.01
W4 64.0 ± 6.4 0.99 0.19 64.0 ± 4.5 0.05 0.63 60.7 ± 8.9 0.99 0.00
W6 65.2 ± 7.9 0.04 0.32 66.7 ± 4.8 0.01 1.17 61.0 ± 8.2 0.99 0.03

PMLSS [W] W0 259.7 ± 67.6     269.1 ± 52.0     260.8 ± 65.9    
W2 271.1 ± 54.7 0.87 0.19 283.6 ± 46.8 0.09 0.29 263.6 ± 60.8 0.99 0.04
W4 278.1 ± 56.0 0.24 0.30 284.6 ± 53.2 0.04 0.29 261.9 ± 64.5 0.99 0.02
W6 284.7 ± 58.7 0.01 0.40 300.8 ± 58.4 0.01 0.57 263.6 ± 61.5 0.99 0.04

Note: Plus-minus values are means ± standard deviation. Abbreviations: CG denotes control group, d Cohen’s d for rating of effect intensity of week two (W2), four (W4) and six (W6) in comparison to baseline (W0) (<0.2 trivial; 0.2 ≤ ǀdǀ <0.5 small; 0.5 ≤ ǀdǀ <0.8 moderate; ǀdǀ ≥ 0.8 large effect size), ET endurance training, Ladiff LamaxPost – LaPre, LamaxPost maximum post exercise blood lactate, LaPre blood lactate previous to test start, p p-values for comparisson of W0 with W2, W4 and W6, Pmax maximum physical power, PMLSS power in calculated maximal lactate steady state, SD standard deviation, SDp15 standard deviation of power per round over the 15 s sprint test, SIT sprint interval training, talac alactic time interval, ⩒Lamax maximal lactate production rate, ⩒O2max maximum oxygen consumption at maximum load.